151 related articles for article (PubMed ID: 11448799)
1. Suggested guidelines for the use of tacrolimus in cardiac transplant recipients.
Taylor DO; Barr ML; Meiser BM; Pham SM; Mentzer RM; Gass AL
J Heart Lung Transplant; 2001 Jul; 20(7):734-8. PubMed ID: 11448799
[No Abstract] [Full Text] [Related]
2. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.
Lindenfeld J; Miller GG; Shakar SF; Zolty R; Lowes BD; Wolfel EE; Mestroni L; Page RL; Kobashigawa J
Circulation; 2004 Dec; 110(25):3858-65. PubMed ID: 15611389
[No Abstract] [Full Text] [Related]
3. Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients.
Teebken OE; Strüber M; Harringer W; Pichlmaier MA; Haverich A
Transplant Proc; 2002 Jun; 34(4):1265-8. PubMed ID: 12072335
[No Abstract] [Full Text] [Related]
4. The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels.
Meiser BM; Pfeiffer M; Schmidt D; Ueberfuhr P; Reichenspurner H; Paulus D; von Scheidt W; Kreuzer E; Seidel D; Reichart B
Transplant Proc; 1999; 31(1-2):84-7. PubMed ID: 10083018
[No Abstract] [Full Text] [Related]
5. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil.
Dipchand AI; Pietra B; McCrindle BW; Rosebrook-Bicknell HL; Boucek MM
J Heart Lung Transplant; 2001 Oct; 20(10):1035-43. PubMed ID: 11595558
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with Prograf (tacrolimus, FK 506) in Chinese patients after renal transplantation.
Yu L; Wang Y; Fu SJ; Cheng XJ
Transplant Proc; 2000 Nov; 32(7):1709-10. PubMed ID: 11119902
[No Abstract] [Full Text] [Related]
7. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
Guethoff S; Meiser BM; Groetzner J; Eifert S; Grinninger C; Ueberfuhr P; Reichart B; Hagl C; Kaczmarek I
Transplantation; 2013 Feb; 95(4):629-34. PubMed ID: 23423270
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
9. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection.
Yamani MH; Starling RC; Goormastic M; Van Lente F; Smedira N; McCarthy P; Young JB
Transplantation; 2000 Jun; 69(11):2326-30. PubMed ID: 10868634
[TBL] [Abstract][Full Text] [Related]
10. New immunosuppressive agents in clinical use: mycophenolate mofetil and tacrolimus.
Hunt SA
Cardiol Rev; 2000; 8(3):180-4. PubMed ID: 11174892
[TBL] [Abstract][Full Text] [Related]
11. The value of routine monitoring of mycophenolic acid plasma levels after clinical heart transplantation.
Hesse CJ; Vantrimpont P; van Riemsdijk-van Overbeeke IC; van Gelder T; Balk AH; Weimar W
Transplant Proc; 2001 May; 33(3):2163-4. PubMed ID: 11377487
[No Abstract] [Full Text] [Related]
12. Hypomagnesia and arrhythmia corrected by replacing cyclosporine with FK506 in a heart transplant recipient.
Ko WJ; Lin FL; Wang SS; Chu SH
J Heart Lung Transplant; 1997 Sep; 16(9):980-2. PubMed ID: 9322151
[No Abstract] [Full Text] [Related]
13. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T
Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
[TBL] [Abstract][Full Text] [Related]
14. Benefits of mycophenolate mofetil in cardiac transplant recipients with cyclosporine-induced nephropathy.
Sánchez V; Delgado JF; Blasco T; Dalmau R; Morales JM; Escribano P; Tello R; Hernández J; Velázquez T; Sotelo T; Gómez-Sánchez MA; Sáenz de la Calzada C
Transplant Proc; 1999 Sep; 31(6):2515-6. PubMed ID: 10500695
[No Abstract] [Full Text] [Related]
15. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring.
Meiser BM; Pfeiffer M; Schmidt D; Reichenspurner H; Ueberfuhr P; Paulus D; von Scheidt W; Kreuzer E; Seidel D; Reichart B
J Heart Lung Transplant; 1999 Feb; 18(2):143-9. PubMed ID: 10194038
[TBL] [Abstract][Full Text] [Related]
16. Conversion from tacrolimus to neoral for postrenal transplant diabetes.
Butani L; Makker SP
Pediatr Nephrol; 2000 Dec; 15(3-4):176-8. PubMed ID: 11149106
[TBL] [Abstract][Full Text] [Related]
17. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
18. Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report.
Jurewicz WA
Transplant Proc; 1999 Nov; 31(7A):64S-66S. PubMed ID: 10576048
[No Abstract] [Full Text] [Related]
19. Nephrotoxicity of ciclosporin A: short-term gain, long-term pain?
Chapman JR; Nankivell BJ
Nephrol Dial Transplant; 2006 Aug; 21(8):2060-3. PubMed ID: 16728428
[No Abstract] [Full Text] [Related]
20. [Immunosuppressive drug monitoring of cyclosporine, tacrolimus, and mycophenolate mofetil in renal transplantation].
Uchida K
Nihon Jinzo Gakkai Shi; 2005; 47(4):423-9. PubMed ID: 15971884
[No Abstract] [Full Text] [Related]
[Next] [New Search]
